Consort Medical Plc (LON:CSRT) has announced that all supply agreements for Voke, an MHRA approved nicotine inhaler, have been terminated with immediate effect by Bespak’s partner, Nicovations. Termination was a contractual right in the event that Voke was not commercially launched before end-2016. Nevertheless, ‘constructive’ talks about Voke’s future continue between Nicovations (holder of distribution rights), Kind Consumer (developer of the product and underlying technology) and Bespak (formerly responsible for build, manufacturing and supply of filled devices and valve technology). Given cessation of the supply contract and uncertainty over Voke’s path to market, we remove it from our pipeline rNPV; this lowers our valuation range for Consort to 1,238-1,300p/share.
Voke: Failure to launch (by 31 December 2016)
Bespak and Nicovations entered into the supply agreements for Voke in 2011, which was subsequently approved by the MHRA in 2014 as a nicotine inhaler for harm reduction in smoking. BAT/Nicovations has made no formal announcement for the reason(s) behind the delayed launch of Voke.
To read the entire report Please click on the pdf File Below